Haemonetics stock jumps on CSL Plasma device rollout plan

Haemonetics Corp. stock climbed 16.1% in morning trading on Thursday after CSL Plasma said it plans to deploy Haemonetics' NexSys PCS devices with Persona PLUS technology across all of its current U.S. plasma collection centers by the end of 2027.

CSL Plasma disclosed the rollout plan in an 8-K regulatory filing on Thursday. The commitment covers more than 300 U.S. donation centers operated by CSL.

The two companies had signed a non-exclusive supply agreement on Aug. 18, 2026, which included no minimum volume commitments. The latest announcement represents a shift to a full-network commitment.

BTIG raised its price target on Haemonetics to $130 from $110 and maintained a Buy rating on the stock. The firm expanded its valuation multiple to 21 times from approximately 18.5 times.

Analysts had previously estimated that a complete transition by CSL could generate between $183 million and $223 million in annual revenue for Haemonetics over several years of rollout.

The stock reached an intraday high of $120.72, marking a fresh 52-week high.

You May Also Be Interested In

• Starbucks Has Explored Takeover Of Chipotle - FT
• Nebius stock drops nearly amid insider sale concerns
• JetBlue Airways (JBLU) 10K contracts of December 2 puts trade